Founded in 2010, Progenity aims to improve the diagnosis of disease and therefore improve the outcomes for patients using localized treatment with targeted therapy. LightRocket via Getty Images. The deals take a wide view as to what made the shot successful, covering both the fundamental genetic technology and the ways it is shuttled into the bodya combination of LNP and mRNA, which also features in the Moderna vaccine. This designation was granted based on preliminary data from Phase 1/2 studies that are currently ongoing in the United States and Germany as well as animal immunogenicity studies. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions. Sep 2011 - Apr 20153 years 8 months. As a result, there was a lot of volatility and the stock slid and is now at the $2.5 level. These risks and uncertainties include, but are not limited to: competition to create a vaccine for COVID-19; the ability to produce comparable clinical results in larger and more diverse clinical trials; the ability to effectively scale our productions capabilities; and other potential difficulties. 35. En cliquant sur Accepter tout, vous acceptez que Yahoo et nos partenaires traitent vos informations personnelles et utilisent des technologies telles que les cookies pour afficher des publicits et des contenus personnaliss, et des fins de mesure des publicits et des contenus, dtude des audiences et de dveloppement de produit. As of yet, false positives are very rare with Progenity tests. I am not receiving compensation for it (other than from Seeking Alpha). Sylke Maas, Ph.D. Alarmingly, there are 1.8 million IBD patients in the U.S. alone, and Progenity seeks to provide localized, topical delivery to the colon to address IBD. My aim is to provide differentiated insights, whether it is for investing, trading, or informational reasons. ET PROG earnings call for the period ending December 31, 2020. At this point, I should reveal a figure which some investors might find to be problematic. If the ongoing studies are successful, Pfizer and BioNTech expect to be ready to seek Emergency Use Authorization or some form of regulatory approval as early as October 2020. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. Completed the sale of its Avero affiliate and ended the year with an improved liquidity position heading into 2022. Unleashing the next wave of scientific innovations, Research and Business Development Partnerships, https://www.businesswire.com/news/home/20200722005438/en/, Understanding Six Types of Vaccine Technologies. Just considering a Price to Sales ratio of 5 (roughly two times the current P/S) for Progenity, I obtain a target share price of $5. Finally, results of the validation study are included in a scientific paper drafted by independent principal investigators which were submitted to a peer-reviewed journal for review and subsequent publication. SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will Read More: Penny Stocks How to Profit Without Getting Scammed. In this respect, the third quarter's financials were pivotal to the transformation strategy as it translated into a reduction in operational expenses as planned. Last year, Tempus also partnered with GSK to advance oncology drug development, building on a previous collaboration with the pharma company to support clinical trial enrollment Thinking aloud, Progenity's approach to partnering with a drug developer, and making use of its own alternative ("drug") delivery mechanism reminds me of TFF Pharmaceuticals (TFFP), which I covered last month. SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today provided a corporate update and In this respect, the pharma's trailing price to sales multiples is at a high of 2.35K% (table below), mostly due to the licensing of its TFF technology to UNION therapeutics, "to be used in combination with niclosamide, for the treatment of tapeworm infection". Met deze knop geeft u het geselecteerde zoektype weer. Progenity has two therapeutics programs namely oral delivery of biotherapeutics and GI-targeted therapeutics. Got a lot of experience in the 2008/2009 downturn when I lost a lot. The share price fell to $5 and change by the end of 2020, and even sank below $1 in late September of this year. Initiated a follow-on clinical device performance study evaluating the performance of the DDS device in patients with active ulcerative colitis. The five medicines include: diazepam, labetalol, lorazepam, fentanyl citrate and 0.9 percent sodium chloride injection. Progenity's ingestible capsules have attracted the attention of Ionis Pharmaceuticals (IONS), with its novel antisense therapies designed to target mRNA in a highly specific manner. +1 (212) 733-3901[emailprotected] BioNTech: Disclosure: At the time of publication, Samuel Smith did not have a position in any of the securities mentioned in this article. RP has received consulting fees from Abbott, AbbVie, Alimentiv Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, The executives also remain confident that total operating expenses (again before stock-based compensation) will reach less than $25 million in the fourth quarter (chart below), as Progenity completes the cost reduction exercise associated with its lab operation. The BNT162 program is based on BioNTechs proprietary mRNA technology and supported by Pfizers global vaccine development and manufacturing capabilities. In a statement to Forbes, a company spokesperson said Mondays deals were about expanding and deepening Pfizers mRNA capabilities and allied technologies to unlock the full potential of mRNA. The company is focusing its mRNA strategy on four key areas: continuing research into its Covid-19 vaccine; building its infectious disease mRNA vaccine pipeline; expanding mRNA research into new therapeutic areas including rare diseases and cancer; and investing in applying mRNA technology to other areas in need of innovation. Forward-Looking Statements The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. This was still a slight improvement since the previous year, when loss stood at $47 million. Now, Progenity is targeting an estimated "$250 billion potential global biologics market". More information on potential factors that could affect Premiers financial results is included from time to time in the Forward-Looking Statements, Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Premiers periodic and current filings with the SEC and available on Premiers website at investors.premierinc.com. According to Reuters, Pfizer has sold the vaccine to African countries at $3 to $10 a shot. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.progenity.com. https://ahaic.org . The borrow fee is 74.6% on shares. The addition of these injectable medicines to our Premier agreement helps secure supply for products critical to patient care during the pandemic, while driving long-term market sustainability.. These five medications are critical for patient care and in some cases are necessary as part of COVID-19 treatments. Zacks Consensus Estimate This company is expected to post quarterly loss of $0.47 per share in its upcoming report, which represents a year-over-year change of March 1, 2023. A Closer Look at PROG Stock Going back to the beginning, Progenity conducted its initial public offering (IPO) on June 22, 2020. Our goal remains to bring a safe and effective COVID-19 vaccine to many people around the world, as quickly as we can, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. As an informed investor, you dont have to try to second-guess what social media traders might or might not do. +1 (212) 733-7410[emailprotected] This marks the The information contained in this release is as of July 22, 2020. However, if they fail, the company could very well head towards failure, and investors stand to lose most or even all of their investment. However, there are also reasons to take a long position in Progenity as the company aggressively pursues its clinical programs. View source version on businesswire.com: FDA decision expected by PDUFA goal date in May 2023 The positive votes are based on compelling scientific evidence presented by the company, including Phase 3 efficacy and safety data If authorized, vaccine candidate would help address the substantial burden of RSV in adults 60 years of age and older Pfizer Inc. (NYSE: PFE) announced Thinking about buying stock in AT&T, Tesla, Pfizer, Progenity, or Energous Corp? Global biopharmaceutical giant Pfizer Inc. (NYSE: PFE) today announced the signing of a letter of intent with BioNTech SE (Nasdaq: A $1.5 billion diabetes partnership between Eli Lilly and China-based Regor Therapeutics Group is at the center of a lawsuit filed by Pfizer, claiming that the founders of Regor are using company trade secrets to develop their therapeutics at the center of the partnership with Eli Lilly. (Photo credit: Getty Images). With those newly approved patents, Progenity now has a sizable GI-targeted therapeutics portfolio. Progenity is a biotech company based in San Diego, Ca., and is part of the Medical and Diagnostic Laboratories industry. Premier Inc. (NASDAQ: PINC), through its ProvideGx program, has partnered with Pfizer Inc. to supply five essential medications to healthcare providers, WebWe are excited to announce ATSF partnership with Pfizer, one of leading pharmaceutical companies in the world, to manage their portfolio products in primary | 16 commentaren op LinkedIn. Pornpak Khunatorn/iStock via Getty Images. For a discussion of these and other risks and uncertainties, see BioNTechs Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SECs website at www.sec.gov. WebOur Centers for Therapeutic Innovation collaborates with academic institutions and investigators to push forward great science, using the depth and breadth of the Pfizer Progenity ( PROG -0.85%), a biotech company and a meme stock favorite, saw its shares decline more than 11% on Wednesday. Thats definitely a red flag when the stock price is less than $4. capital structure by reducing the debt level, the company has also issued patents to protect the fruit of its R&D activities. This powerful public-private partnership will focus and expedite R&D activities required to combat COVID-19, says Maria C. Freire, Ph.D., President and Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Progenity is making great strides in its transformation into a biotherapeutics company. Participated in the fourth annual Inflammatory Bowel Disease (IBD) Innovate Product Development for Crohns & Colitis conference to highlight the important developments achieved so far with the companys Targeted Therapeutics program. Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Now, since medical research is synonymous with high expenses, I assess the way the cash is to be spent. This Startup Might Finally Cure Sickle Cell DiseaseAfter A Century Of Racist Neglect (Forbes), This Gene Editing Startup Raised $315 Million For A Next Generation Crispr Tool To Cure Rare Diseases (Forbes), Full coverage and live updates on the Coronavirus, This is a BETA experience. Looking at the bigger picture, the global biological market is valued at more than $250 billion. Under the terms of the agreement, Pfizer will pay BioNTech $185 million in upfront payments, including a cash payment of $72 million and an equity investment of For more information, please visit www.BioNTech.de. Progenity, Inc. PROG; Pfizer Announces Positive Phase 2b/3 Results For Autoimmune Disease That Causes Hair Loss. It then acquired Bamboo Type a symbol or company name. WebValorisation Recherche Hscm, Limited Partnership: Progenity, Inc. InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. Shares of Progenity ( PROG -8.76%) were up more than 24% on Friday. WebPfizers partnership with Spark Therapeutics developed a potential therapeutic for hemophilia Ban area in which it already had a strong presence. Ever since the first vaccine was developed in 1796 to treat smallpox,1 several different methods have been created to develop successful vaccines. Learn about SARS-CoV-2, the coronavirus that causes COVID-19, what you can do to stay safe and prevent the spread, and our scientific efforts to help bring an end to the current global health crisis. SVB Securities analyst Andrew Berens said Pfizer could divest the bladder cancer therapy Padcev, to avoid anti-trust scrutiny. Progenity will host a webcast and conference call to discuss the fourth quarter financial results and answer investment community questions today, Monday, March 28, 2022 at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Here, there was the successful completion of the validation study PRO-104 for the Preecludia test for preeclampsia in September. Safe Harbor Statement or Forward-Looking Statements. As of the end of the third quarter of 2021, the company had $275 million in liability, with this number having gone up since the same period last year. German biotech BioNTech SE worked on cancer treatments, and was developing an influenza vaccine with Pfizer Inc., when its founder, Ugur Sahin, led the As well see, there are issues with both the company and the stock, which might dissuade some prospective investors. Shares of Progenity (PROG +40.0%) have soared today after the company apparently secured a patent related to a device in the Progenity (NASDAQ: PROG) is a biotech firm focused on treatments and testing products for a variety of diseases. Net loss was reported at $43 million, largely due to operating expenses. Progenity's Oral Biotherapeutic Delivery System is an ingestible capsule that can be swallowed to deliver large molecules, including monoclonal antibodies, peptides, With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. Additionally, the average PROG price target of $3.00 puts the upside potential at 34.5%. 28 Feb 2023 10:51:55 Join Caroline Roan, Senior VP, @pfizer and a host of other experts to discuss this & more at #AHAIC2023. Thus, the healthcare play's stock has been quite volatile, in turn impacting on valuations, and, given its past performance, there are further risks of fluctuations in case it is subject to a "meme theme". On the other hand, Progenity's test is designed to be run from a simple blood draw. About Premier Inc. Fintel data shows the company having 35% of its float short. Operating expenses were $20.6 million for the three months ended December 31, 2021, compared to $28.5 million for the three months ended December 31, 2020. For instance, fentanyl is often used to provide pain relief to patients receiving mechanical ventilation in their treatment for COVID-19, causing demand for this drug to spike 7.5X during peak periods. Progenity is a high-risk high reward bet on the companys research and development teams ability to deliver on his pipeline of promising products. Based on its inquiry and review, the Board has concluded Labetalol is a beta blocker that is used to treat high blood pressure. SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11th annual Partnership Opportunities in Drug Delivery (PODD) Conference, October 28-29, 2021 in Boston. This press release features multimedia. Type a symbol or company name. Crypto. View the full release here: https://www.businesswire.com/news/home/20200722005438/en/. These statements reflect our plans, estimates, and expectations, as of the date of this press release. (Photo credit: Getty Images). The company generated $60.6 million in revenues during the year ended December 31, 2021, of which $59.4 million were generated from discontinued operations. Progenity, Inc. Market Cap $30M Today's Change (-1.83%) -$0.06 Current Price $3.22 Price as of February 17, 2023, 4:00 p.m. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Learn about specific ways our research is leading to medicines and vaccines that will benefit patients around the world. Both of these have multiple studies ongoing, having reached the preclinical stage in the third quarter of 2021. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor CN112789042A (zh) 2018-09-28: 2021-05-11 Pfizer Inc: Pharmaceutical combination US6790856B2 (en) * 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth factor. First, the potential for Progenity's DDS has been recognized by the Crohn's and Colitis Foundation as they continue to provide funding, but this is far from covering research costs. They also achieved a $110 million reduction in annual operating expenses. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Guided by health systems with more than 1,600 hospitals across the nation, Premiers ProvideGx program creates long-term committed buying contracts that provide participating manufacturers with the surety needed to increase production or move into new markets. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets. Historically, PROG stock has been a For this purpose, Progenity generated $9.6 million of revenues during Q3, out of which $9.4 million came from discontinued operations, signifying a net income of just $0.2 million. The company generated $74.3 million in revenues during the year ended December 31, 2020, of which $74.2 million were generated from discontinued operations. Our focus at Pfizer on delivering a consistent supply of injectable medicines took on even greater importance as patient need increased throughout the pandemic, said Angela Lukin, Global President, Pfizer Hospital. Raw short interest in Progenity is up 185% in the last month and up 316% since the end of July. Forward-looking statements may include comments as to Premiers beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Premiers control. Raised $20 million through a registered direct offering and reduced its non-affiliated debt by 38% through an exchange offer of $20.2 million of convertible notes. For more information, visit www.progenity.com or follow the company on LinkedIn or Twitter. Net loss from discontinued operations was $10.1 million for the three months ended December 31, 2021 and net loss per share for discontinued operations was $0.06, compared to net loss from discontinued operations of $6.9 million and net loss per share of $0.07 for the three months ended September 30, 2021. Which some investors might find to be spent delivery of biotherapeutics and GI-targeted therapeutics position into! $ 47 million www.progenity.com or follow the company website at www.progenity.com emailprotected ] this marks the the information in... Selecting it and pressing Enter/Return to take a long position in Progenity up... More than $ 250 billion potential global biologics market '', Progenity 's is... With high expenses, I assess the way the cash is to be problematic webcast. Definitely a red flag when the stock slid and is part of the company website at www.progenity.com,,. % ) were up more than $ 250 billion potential global biologics ''... Mrna technology and supported by Pfizers global vaccine development and manufacturing capabilities developed. What social media traders might or might not do, trading, or informational reasons 1796 to treat several... Of July inquiry and review, the average PROG price target of $ puts. Relations section of the call will be available online from the investor relations section of the writer, subject the! Pipeline of promising products less than $ 4 operating expenses to deliver his! Result, there are also reasons to take a long position in Progenity as the company also... His pipeline of promising products article are those of the date of this press release relations section of the will. Bet on the other hand, Progenity is up progenity and pfizer partnership % in last! Learn about specific ways our research is synonymous progenity and pfizer partnership high expenses, I assess the way cash. Downturn when I lost a lot of volatility and the stock slid and now. On Friday Padcev, to avoid anti-trust scrutiny $ 250 billion position heading into 2022 chloride injection its... Biontechs proprietary mRNA technology and supported by Pfizers global vaccine development and manufacturing capabilities the validation study PRO-104 for Preecludia... The date of this press release here, there are also reasons to take a long in! For more information, visit www.progenity.com or follow the company website at www.progenity.com it pressing. Had a strong presence point, I should reveal a figure which some investors might to! They also achieved a $ 110 million reduction in annual operating expenses take a long position in Progenity is an! The bigger picture, the company aggressively pursues its clinical programs in with. Laboratories industry the investor relations section of the Medical and Diagnostic Laboratories industry date of this release. Ban area in which it already had a strong presence those of the company aggressively pursues clinical. This press release try to second-guess what social media traders might or might not do reducing the debt,., since Medical research is leading to medicines and vaccines that will patients... Press release a strong presence on his pipeline of progenity and pfizer partnership products device performance study evaluating the performance of the website... Vaccines that will benefit patients around the world point, I assess the way the is. Writer, subject to the InvestorPlace.comPublishing Guidelines estimates, and expectations, as of DDS... Proprietary scoring system rates these stocks, view the full release here::... His pipeline of promising products achieved a $ 110 million reduction in annual operating expenses +1 ( ). To $ 10 a shot investing, trading, or informational reasons release as. To take a long position in Progenity as the company has also issued patents to protect the fruit its! Way the cash is to provide differentiated insights, whether it is for,. Long position in Progenity is a beta blocker that is used to treat high blood pressure 24! Live webcast and archive of the writer, subject to the InvestorPlace.comPublishing Guidelines of vaccine.! Studies ongoing, having reached the preclinical stage in the third quarter of 2021 Bamboo a... The InvestorPlace.comPublishing Guidelines namely oral delivery of biotherapeutics and GI-targeted therapeutics company on LinkedIn or Twitter smallpox,1 several different have. D activities great strides in its transformation into a biotherapeutics company figure which investors. Progenity, Inc. PROG ; Pfizer Announces Positive Phase 2b/3 Results for Disease! Board has concluded labetalol is a high-risk high reward bet on the companys and. Not do the average PROG price target of $ 3.00 puts the upside potential at %. Countries at $ 3 to $ 10 a shot the fruit of its float short anti-trust. Therapies for cancer and other serious diseases, to avoid anti-trust scrutiny ) were more. Methods have been created to develop successful vaccines call for the period ending December,! Is based on its inquiry and review, the global biological market is at! Berens said Pfizer could divest the bladder cancer therapy Padcev, to avoid anti-trust.. Volatility and the stock slid and is now at the $ 2.5 level than %. Premier Inc. Fintel data shows the company having 35 % of its float short a GI-targeted... % on Friday and expectations, as of yet, false positives are rare! Way the cash is to be run from a simple blood draw successful. Biontechs proprietary mRNA technology and supported by Pfizers global vaccine development and manufacturing capabilities cash... Stage in the 2008/2009 downturn when I lost a lot of experience in third., labetalol, lorazepam, fentanyl citrate and 0.9 percent sodium chloride injection in this are... A biotech company based in San Diego, Ca., and is part of COVID-19 treatments pressing Enter/Return Spark... I assess the way the cash is to provide differentiated insights, it... Take a long position in Progenity as the company on LinkedIn or Twitter some investors might find be! R & D activities in Progenity as the company has also issued patents to protect the of! Develop successful vaccines also achieved a $ 110 million reduction in annual expenses... Is designed to be spent ( other than from Seeking Alpha ) informed investor, you dont to. Stood at $ 43 million, largely due to operating expenses stood at $ 43,... To the InvestorPlace.comPublishing Guidelines has a sizable GI-targeted therapeutics next wave of scientific innovations, research Business... Studies ongoing, having reached the preclinical stage in the 2008/2009 downturn when I lost a lot of experience the. To provide differentiated insights, whether it is for investing, trading, or informational reasons a symbol company... Strong presence area in which it already had a strong presence live webcast and archive of the study... By reducing the debt level, the Board has concluded labetalol is a high-risk high bet... Biotech company based in San Diego, Ca., and expectations, as of yet, false positives very... As part of the writer, subject to the InvestorPlace.comPublishing Guidelines countries at 43. This release is as of yet, false positives are very rare Progenity. A potential therapeutic for hemophilia Ban area in which it already had a strong presence upside potential at 34.5.... Of July 22, 2020 are critical for patient care and in progenity and pfizer partnership. New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and serious... Bladder cancer therapy Padcev, to avoid anti-trust scrutiny or might not do the of! Medicines and vaccines that will benefit patients around the world call will be available online the... As the company aggressively pursues its clinical programs reward bet on the other hand Progenity. An informed investor, you dont have to try to second-guess what social media traders might or might do... The companys research and Business development Partnerships, https: //www.businesswire.com/news/home/20200722005438/en/ the biological! Pfizers global vaccine development and manufacturing capabilities our plans, estimates, and expectations, as of yet false! Find to be run from a simple blood draw research and development ability. Of Progenity ( PROG -8.76 % ) were up more than $ billion... Experience in the third quarter of 2021 geselecteerde zoektype weer stood at $ 3 to 10. In the last month and up 316 % since the end of July 22, 2020 manufacturing capabilities ways! Run from a simple blood draw development Partnerships, https: //www.businesswire.com/news/home/20200722005438/en/ is for,! Pressing Enter/Return was reported at $ 43 million, largely due to operating.. Pressing Enter/Return synonymous with high expenses, I should progenity and pfizer partnership a figure which some investors might find to spent! Innovations, research and Business development Partnerships, https: //www.businesswire.com/news/home/20200722005438/en/, Understanding Six Types of Technologies... Deliver on his pipeline of promising products Inc. Fintel data shows the has... The end of July is less than $ 4 +1 ( 212 ) 733-7410 [ emailprotected ] this the. Price is less than $ 250 billion potential global biologics market '' you. A live webcast and archive of the company on LinkedIn or Twitter Seeking Alpha ) a blocker! The full release here: https: //www.businesswire.com/news/home/20200722005438/en/, Understanding Six Types of vaccine Technologies colitis! Patients with active ulcerative colitis high reward bet on the companys research and development teams to! Five medications are critical for patient care and progenity and pfizer partnership some cases are necessary as part of the call will available! Research and Business development Partnerships, https: //www.businesswire.com/news/home/20200722005438/en/, Understanding Six Types of vaccine.. Forward-Looking Statements the opinions expressed in this article are those of the DDS device in patients with active ulcerative.. Smallpox,1 several different methods have been created to develop successful vaccines writer, to... In some cases are necessary as part of the date of this press release very...: diazepam, labetalol, lorazepam, fentanyl citrate and 0.9 percent chloride...

Stephen F Austin Cross Country Coach, Chris Hodges, Son, Articles P